A cost-effectiveness method for detection of ABL mutations in patients who developed Imatinib resistance WCRJ 2016; 3 (4) : e799 DOI: 10.32113/wcrj_201612_799
Recent evolutions on cancer clinical aspects and therapeutics approach. Naples (Italy) 11-12 July 2016 WCRJ 2016; 3 (4) : e790 DOI: 10.32113/wcrj_201612_790
Nutraceutical agents with hepatoprotective effects in cancer patients WCRJ 2016; 3 (4) : e788 DOI: 10.32113/wcrj_201612_788
Commentary – Beliefs and preferred communication channels toward patients with cancer in Jordan WCRJ 2016; 3 (4) : e786 DOI: 10.32113/wcrj_201612_786
Beliefs and preferred communication channels toward patients with cancer in Jordan WCRJ 2016; 3 (3) : e753
Hepatocellular carcinoma in HCV cirrhosis after viral clearance with direct acting antiviral therapy: preliminary evidence and possible meanings WCRJ 2016; 3 (3) : e748
Over expression of the fatty acid synthase is a strong predictor of poor prognosis and contributes to glucocorticoid resistance in B-cell acute lymphoblastic leukemia WCRJ 2016; 3 (3) : e746
Evaluation of clinical and economic impact of pharmacogenomics testing in taxanes-based therapy WCRJ 2016; 3 (3) : e744